Pulmonary Emphysema Therapeutics Market Size in the 7MM is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Pulmonary Emphysema Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pulmonary Emphysema, historical and forecasted epidemiology as well as the Pulmonary Emphysema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To know in detail about the Pulmonary Emphysema market outlook, drug uptake, treatment scenario and epidemiology trends @ https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pulmonary Emphysema Market Report
• In 2024, approximately 4.01 million adults in the US were estimated to have emphysema.
• Among the EU4 and the UK, Germany accounted for the highest cases of emphysema with approximately 1.37 million cases, followed by Italy with 0.97 million cases in 2024, whereas the UK accounted for the least cases of emphysema in the same year.
• The highest prevalence of emphysema is observed among individuals aged 55 to 65 years and older, indicating an increased risk of disease with advancing age.
• In Japan, the prevalence of airflow obstruction consistent with COPD, which includes emphysema, ranges between approximately 3.8% and 16.9% depending on the study and population. Large database studies estimate COPD prevalence around 8.6% among those aged 40 and older, with low diagnosis rates despite spirometry testing in health checkups.
• The leading Pulmonary Emphysema Companies such as Sanofi, Chiesi Farmaceutici S.p.A., GSK Pharmaceuticals, Regeneron Pharmaceuticals, Verona Pharma, Uniquity Bio, Palobiofarma, BioMarin Pharmaceutical and others.
• Promising Pulmonary Emphysema Therapies such as BLVR Treatment, Exhale Drug-Eluting Stent, Alpha-1 MP, RAR Gamma, ProchymalTM, SAR447537, and others

Get a Free sample for the Pulmonary Emphysema Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Emphysema Overview
Pulmonary emphysema is a chronic lung condition characterized by the destruction of alveoli (air sacs) in the lungs, leading to reduced oxygen exchange and breathing difficulties. It is a form of chronic obstructive pulmonary disease (COPD) and is primarily caused by long-term smoking, air pollution, or genetic factors like alpha-1 antitrypsin deficiency. Symptoms include shortness of breath, chronic cough, wheezing, and fatigue. There is no cure, but treatments such as bronchodilators, corticosteroids, oxygen therapy, and pulmonary rehabilitation can help manage symptoms and improve quality of life.

Pulmonary Emphysema Epidemiology Segmentation in the 7MM
• Total Prevalence of Pulmonary Emphysema
• Prevalent Cases of Pulmonary Emphysema by severity
• Gender-specific Prevalence of Pulmonary Emphysema
• Diagnosed Cases of Episodic and Chronic Pulmonary Emphysema

Download the report to understand which factors are driving Pulmonary Emphysema epidemiology trends @ https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Emphysema Marketed Drugs
• Ensifentrine (OHTUVAYRE): Verona Pharma /Merck
Ensifentrine is a first-in-class, selective dual inhibitor of PDE3 and PDE4, designed to provide both bronchodilatory and nonsteroidal anti-inflammatory effects within a single molecule. In the ENHANCE-1 and ENHANCE-2 trials, ensifentrine achieved its primary endpoints, showing statistically significant and clinically relevant improvements in lung function. A fixed-dose combination of ensifentrine with the LAMA glycopyrrolate is also being developed for maintenance treatment in patients with COPD. Beyond COPD, ensifentrine holds potential therapeutic applications in pulmonary emphysema.

• Dupilumab (DUPIXENT): Regeneron Pharmaceuticals/Sanofi
Dupilumab is a first-in-class, fully human monoclonal antibody that targets the IL-4 receptor alpha subunit, thereby inhibiting signaling of both IL-4 and IL-13, key drivers of type 2 inflammation. Through this dual mechanism, it provides broad anti-inflammatory effects across multiple atopic and respiratory diseases. Dupilumab has demonstrated significant and clinically meaningful improvements in lung function and symptom control in clinical trials for asthma and COPD. It is approved for several type 2 inflammatory conditions, and ongoing development explores its potential role in additional indications, including pulmonary emphysema.

Pulmonary Emphysema Emerging Drugs
• SAR447537: Sanofi
SAR-447537 (formerly INBRX-101) is an investigational recombinant fusion protein being developed by Sanofi for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder that can cause pulmonary emphysema. Designed as a long-acting AAT-Fc fusion protein, it aims to maintain protective AAT levels in serum and lung tissue with dosing every three to four weeks, unlike current plasma-derived therapies that require weekly infusions. By protecting alveoli and reducing protease-driven tissue damage, SAR-447537 may help slow emphysema progression. It has orphan drug designation and is being studied in the Phase II ElevAATe trial and a long-term open-label extension. Early results show sustained AAT activity and lung penetration, suggesting potential to improve treatment convenience, adherence, and long-term outcomes for AATD-related emphysema.

• Tanimilast (CHF6001): Chiesi Farmaceutici S.p.A.
CHF6001, also known as Tanimilast, is an anti-inflammatory drug being developed for the treatment of respiratory conditions, including COPD and asthma. Tanimilast functions as a PDE4 inhibitor. By inhibiting PDE4, it prevents the breakdown of cyclic Adenosine Monophosphate (cAMP) within inflammatory cells, leading to reduced inflammation and immune response modulation. This mechanism helps alleviate symptoms and improve lung function in patients with inflammatory respiratory diseases.

Pulmonary Emphysema Therapies and Companies
• BLVR Treatment: Aeris Therapeutics
• Exhale Drug-Eluting Stent: Broncus Technologies
• Alpha-1 MP: Grifols Therapeutics LLC
• RAR Gamma: Hoffmann-La Roche
• ProchymalTM: Mesoblast, Inc
• SAR447537: Sanofi

Discover more about therapies set to grab major Pulmonary Emphysema market share @ https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pulmonary Emphysema Market Outlook
Pulmonary emphysema, a major component of COPD, is characterized by progressive lung tissue destruction, chronic airflow limitation, and high morbidity. Current therapies focus on symptom relief and include bronchodilators (LABAs, LAMAs), inhaled corticosteroids (ICS), combination inhalers such as beclometasone/formoterol/glycopyrronium bromide (TRIMBOW), and mucolytics, which improve airflow and reduce exacerbations but do not halt disease progression. Targeted treatments include biologics and small molecules such as dupilumab (DUPIXENT), mepolizumab (NUCALA), and ensifentrine (OHTUVAYRE) for patients with eosinophilic inflammation or frequent exacerbations. For alpha-1 antitrypsin deficiency (AATD)-related emphysema, plasma-derived AAT augmentation therapy remains the standard to slow lung tissue degradation. Emerging pipeline focuses on disease-modifying approaches to restore functional AAT, protect alveoli, and potentially alter disease progression. Key investigational candidates include Solrikitug (Uniquity Bio), PBF-680 (Palobiofarma), Tanimilast/CHF6001 (Chiesi Farmaceutici S.p.A.), long-acting recombinant AAT fusion proteins (SAR-447537), and small-molecule chaperones (BMN-349).

Pulmonary Emphysema Drugs Landscape
Ensifentrine is the first new inhaled therapy for COPD in over two decades. Approved in June 2024, the drug has demonstrated strong early uptake, reflecting its differentiated profile as both a bronchodilator and anti-inflammatory agent. The rapid adoption underscores physician confidence in its dual mechanism of action and its potential to address unmet needs in COPD management. By leveraging Verona's pipeline alongside OHTUVAYRE's momentum, Merck is positioning itself as a leader in next-generation respiratory care, expanding its portfolio beyond oncology and immunology. Ensifentrine provides Merck with a strategic growth engine in chronic lung disease, an area with significant unmet need and long-term potential.

Scope of the Pulmonary Emphysema Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Pulmonary Emphysema Companies: Sanofi, Chiesi Farmaceutici S.p.A., GSK Pharmaceuticals, Regeneron Pharmaceuticals, Verona Pharma, Uniquity Bio, Palobiofarma, BioMarin Pharmaceutical and others.
• Key Pulmonary Emphysema Therapies: BLVR Treatment, Exhale Drug-Eluting Stent, Alpha-1 MP, RAR Gamma, ProchymalTM, SAR447537, and others
• Pulmonary Emphysema Therapeutic Assessment: Pulmonary Emphysema current marketed and Pulmonary Emphysema emerging therapies
• Pulmonary Emphysema Market Dynamics: Pulmonary Emphysema market drivers and Pulmonary Emphysema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pulmonary Emphysema Unmet Needs, KOL's views, Analyst's views, Pulmonary Emphysema Market Access and Reimbursement

To know more about Pulmonary Emphysema companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Pulmonary Emphysema Market Report Introduction
2. Executive Summary for Pulmonary Emphysema
3. SWOT analysis of Pulmonary Emphysema
4. Pulmonary Emphysema Patient Share (%) Overview at a Glance
5. Pulmonary Emphysema Market Overview at a Glance
6. Pulmonary Emphysema Disease Background and Overview
7. Pulmonary Emphysema Epidemiology and Patient Population
8. Country-Specific Patient Population of Pulmonary Emphysema
9. Pulmonary Emphysema Current Treatment and Medical Practices
10. Pulmonary Emphysema Unmet Needs
11. Pulmonary Emphysema Emerging Therapies
12. Pulmonary Emphysema Market Outlook
13. Country-Wise Pulmonary Emphysema Market Analysis
14. Pulmonary Emphysema Market Access and Reimbursement of Therapies
15. Pulmonary Emphysema Market Drivers
16. Pulmonary Emphysema Market Barriers
17. Pulmonary Emphysema Appendix
18. Pulmonary Emphysema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.